USC Norris

Latest from USC Norris


New Clinical Trial Will Assess Novel ADC in Drug Resistant HER2+ Breast Cancer

October 23, 2021

The recently launched phase 2 ACE-Breast03 seeks to appraise the efficacy and safety of the novel antibody-drug conjugate, ARX788, in patients with metastatic HER2-positive breast cancer whose disease is resistant to previous targeted therapies.